

Table 7. Alendronate (Fosamax) for Paget's disease

Study	Regimens	Treatment Duration	N	Endpoints	Results
Reid et al ¹¹	Alendronate: 40 mg/d or placebo	6 months	55	Serum alkaline phosphatase, N-telopeptide, and radiologic assessment	N-telopeptide and serum alkaline phosphatase decreased by 86% and 73%, respectively (P < 0.001). Adverse events in the treatment group were comparable to placebo. The sample size for this study was small.